Mallory RM, Formica N, Pfeiffer S, Wilkinson B, et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis 2022 Aug 10. pii: S1473-3099(22)00420.
PMID: 35963274